The Rivelin clobetasol patch provides a new ground breaking technology for targeting mucosal ulcers and stomatitis.
The major challenge in treating oral mucosal ulcers and stomatitis is short contact time and low exposure of drug. This leave the patients with severe unmet needs such as:
The Rivelin clobetasol patch takes all the challenges in treating mucosal ulcers and stomatitis into account:
Rivelin Clobetasol patch has in preclinical studies demonstrated adherence to porcine mucosa for up to 2 hours with efficient release of clobetasol to the mucosa.
A phase 2 study with the Rivelin Clobetasol patch will commence in Q4 2017